Directing systemic oncolytic viral delivery to tumors via carrier cells

Cytokine and Growth Factor Reviews

Volumn 21, Issue 2-3, 2010, Pages 119-126

  Nakashima, Hiroshi ^a   Kaur, Balveen ^a   Chiocca, E A ^a  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

Author keywords

Adenovirus; Carrier cells; HSV 1; MSC; NSC; Virus delivery

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; CONDITIONALLY REPLICATING ADENOVIRUS; E1A PROTEIN; MACROGOL; ONCOLYTIC VIRUS; POLYCATION; SURVIVIN;

ADAPTIVE IMMUNITY; ADENOVIRUS; CANCER CELL; CANCER GENE THERAPY; CANCER IMMUNOTHERAPY; CELL HOMING; CELL SURVIVAL; CELL TRANSFER; DNA MODIFICATION; GLIOMA; HERPES SIMPLEX VIRUS 1; HOST RESISTANCE; HUMAN; INNATE IMMUNITY; INTERNALIZATION; LUNG METASTASIS; MALIGNANT NEOPLASTIC DISEASE; MESENCHYMAL STEM CELL; NEURAL STEM CELL; NONHUMAN; ONCOLYTIC VIROTHERAPY; OVARY CANCER; PRIORITY JOURNAL; PROMOTER REGION; REVIEW; STEM CELL TRANSPLANTATION; VESICULAR STOMATITIS VIRUS; VIRUS REPLICATION; ADENOVIRIDAE; CYTOLOGY; GENE VECTOR; GENETIC TRANSDUCTION; GENETICS; MESENCHYMAL STROMA CELL; METABOLISM; NEOPLASMS; NERVE CELL; PHYSIOLOGY; PROCEDURES; STEM CELL; VIROLOGY;

ADENOVIRIDAE; GENETIC VECTORS; HUMANS; MESENCHYMAL STEM CELLS; NEOPLASMS; NEURONS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; STEM CELLS; TRANSDUCTION, GENETIC; VIRUS REPLICATION; MESENCHYMAL STROMAL CELLS;

ADENOVIRIDAE; HUMAN HERPESVIRUS 1;

EID: 77953537092     PISSN: 13596101     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cytogfr.2010.02.004     Document Type: Review

References (70)

1. Aboody K.S., Brown A., Rainov N.G., Bower K.A., Liu S., Yang W., et al. Neural stem cells display extensive tropism for pathology in adult brain: evidence from intracranial gliomas. Proc Natl Acad Sci USA 2000, 97:12846-12851.
2. Herrlinger U., Woiciechowski C., Sena Esteves M., Aboody K.S., Jacobs A.H., Rainov N.G., et al. Neural precursor cells for delivery of replication-conditional HSV-1 vectors to intracerebral gliomas. Mol Ther 2000, 1:347-357.
3. Studeny M., Marini F.C., Champlin R.E., Zompetta C., Fidler I.J., Andreeff M. Bone marrow-derived mesenchymal stem cells as vehicles for interferon-beta delivery into tumors. Cancer Res 2002, 62:3603-3608.
4. Hakkarainen T., Sarkioja M., Lehenkari P., Miettinen S., Ylikomi T., Suuronen R., et al. Human mesenchymal stem cells lack tumor tropism but enhance the antitumor activity of oncolytic adenoviruses in orthotopic lung and breast tumors. Hum Gene Ther 2007, 18:627-641.
5. Yong R.L., Shinojima N., Fueyo J., Gumin J., Vecil G.G., Marini F.C., et al. Human bone marrow-derived mesenchymal stem cells for intravascular delivery of oncolytic adenovirus Delta24-RGD to human gliomas. Cancer Res 2009, 69:8932-8940.
6. Qiao J., Kottke T., Willmon C., Galivo F., Wongthida P., Diaz R.M., et al. Purging metastases in lymphoid organs using a combination of antigen-nonspecific adoptive T cell therapy, oncolytic virotherapy and immunotherapy. Nat Med 2008, 14:37-44.
7. Culver K.W., Ram Z., Wallbridge S., Ishii H., Oldfield E.H., Blaese R.M. In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science 1992, 256:1550-1552.
8. Benedetti S., Pirola B., Pollo B., Magrassi L., Bruzzone M.G., Rigamonti D., et al. Gene therapy of experimental brain tumors using neural progenitor cells. Nat Med 2000, 6:447-450.
9. Coukos G., Makrigiannakis A., Kang E.H., Caparelli D., Benjamin I., Kaiser L.R., et al. Use of carrier cells to deliver a replication-selective herpes simplex virus-1 mutant for the intraperitoneal therapy of epithelial ovarian cancer. Clin Cancer Res 1999, 5:1523-1537.
10. Lee D.H., Ahn Y., Kim S.U., Wang K.C., Cho B.K., Phi J.H., et al. Targeting rat brainstem glioma using human neural stem cells and human mesenchymal stem cells. Clin Cancer Res 2009, 15:4925-4934.
11. Oreffo R.O., Cooper C., Mason C., Clements M. Mesenchymal stem cells: lineage, plasticity, and skeletal therapeutic potential. Stem Cell Rev 2005, 1:169-178.
12. Abdallah B.M., Kassem M. The use of mesenchymal (skeletal) stem cells for treatment of degenerative diseases: current status and future perspectives. J Cell Physiol 2009, 218:9-12.
13. Spaeth E., Klopp A., Dembinski J., Andreeff M., Marini F. Inflammation and tumor microenvironments: defining the migratory itinerary of mesenchymal stem cells. Gene Ther 2008, 15:730-738.
14. Jain R.K., di Tomaso E., Duda D.G., Loeffler J.S., Sorensen A.G., Batchelor T.T. Angiogenesis in brain tumours. Nat Rev Neurosci 2007, 8:610-622.
15. Fehrer C., Brunauer R., Laschober G., Unterluggauer H., Reitinger S., Kloss F., et al. Reduced oxygen tension attenuates differentiation capacity of human mesenchymal stem cells and prolongs their lifespan. Aging Cell 2007, 6:745-757.
16. Djouad F., Bony C., Apparailly F., Louis-Plence P., Jorgensen C., Noel D. Earlier onset of syngeneic tumors in the presence of mesenchymal stem cells. Transplantation 2006, 82:1060-1066.
17. Stoff-Khalili M.A., Rivera A.A., Mathis J.M., Banerjee N.S., Moon A.S., Hess A., et al. Mesenchymal stem cells as a vehicle for targeted delivery of CRAds to lung metastases of breast carcinoma. Breast Cancer Res Treat 2007, 105:157-167.
18. Sonabend A.M., Ulasov I.V., Tyler M.A., Rivera A.A., Mathis J.M., Lesniak M.S. Mesenchymal stem cells effectively deliver an oncolytic adenovirus to intracranial glioma. Stem Cells 2008, 26:831-841.
19. Komarova S., Kawakami Y., Stoff-Khalili M.A., Curiel D.T., Pereboeva L. Mesenchymal progenitor cells as cellular vehicles for delivery of oncolytic adenoviruses. Mol Cancer Ther 2006, 5:755-766.
20. Josiah D.T., Zhu D., Dreher F., Olson J., McFadden G., Caldas H. Adipose-derived stem cells as therapeutic delivery vehicles of an oncolytic virus for glioblastoma. Mol Ther 2009, (November):10.
21. Lazennec G., Jorgensen C. Concise review: adult multipotent stromal cells and cancer: risk or benefit?. Stem Cells 2008, 26:1387-1394.
22. Bexell D., Gunnarsson S., Tormin A., Darabi A., Gisselsson D., Roybon L., et al. Bone marrow multipotent mesenchymal stroma cells act as pericyte-like migratory vehicles in experimental gliomas. Mol Ther 2009, 17:183-190.
23. Rainov N.G., Zimmer C., Chase M., Kramm C.M., Chiocca E.A., Weissleder R., et al. Selective uptake of viral and monocrystalline particles delivered intra-arterially to experimental brain neoplasms. Hum Gene Ther 1995, 6:1543-1552.
24. Ikeda K., Ichikawa T., Wakimoto H., Silver J.S., Deisboeck T.S., Finkelstein D., et al. Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses. Nat Med 1999, 5:881-887.
25. Schellingerhout D., Rainov N.G., Breakefield X.O., Weissleder R. Quantitation of HSV mass distribution in a rodent brain tumor model. Gene Ther 2000, 7:1648-1655.
26. Gage F.H. Mammalian neural stem cells. Science 2000, 287:1433-1438.
27. Ohira K., Furuta T., Hioki H., Nakamura K.C., Kuramoto E., Tanaka Y., et al. Ischemia-induced neurogenesis of neocortical layer 1 progenitor cells. Nat Neurosci 2009, (December):27.
28. Aboody K.S., Najbauer J., Danks M.K. Stem and progenitor cell-mediated tumor selective gene therapy. Gene Ther 2008, 15:739-752.
29. Shen Q., Goderie S.K., Jin L., Karanth N., Sun Y., Abramova N., et al. Endothelial cells stimulate self-renewal and expand neurogenesis of neural stem cells. Science 2004, 304:1338-1340.
30. Zhao D., Najbauer J., Garcia E., Metz M.Z., Gutova M., Glackin C.A., et al. Neural stem cell tropism to glioma: critical role of tumor hypoxia. Mol Cancer Res 2008, 6:1819-1829.
31. Burns T.C., Verfaillie C.M., Low W.C. Stem cells for ischemic brain injury: a critical review. J Comp Neurol 2009, 515:125-144.
32. Glass R., Synowitz M., Kronenberg G., Walzlein J.H., Markovic D.S., Wang L.P., et al. Glioblastoma-induced attraction of endogenous neural precursor cells is associated with improved survival. J Neurosci 2005, 25:2637-2646.
33. Pluchino S., Zanotti L., Rossi B., Brambilla E., Ottoboni L., Salani G., et al. Neurosphere-derived multipotent precursors promote neuroprotection by an immunomodulatory mechanism. Nature 2005, 436:266-271.
34. Martino G., Pluchino S. The therapeutic potential of neural stem cells. Nat Rev Neurosci 2006, 7:395-406.
35. Gilbertson R.J., Rich J.N. Making a tumour's bed: glioblastoma stem cells and the vascular niche. Nat Rev Cancer 2007, 7:733-736.
36. Brown A.B., Yang W., Schmidt N.O., Carroll R., Leishear K.K., Rainov N.G., et al. Intravascular delivery of neural stem cell lines to target intracranial and extracranial tumors of neural and non-neural origin. Hum Gene Ther 2003, 14:1777-1785.
37. Frank R.T., Edmiston M., Kendall S.E., Najbauer J., Cheung C.W., Kassa T., et al. Neural stem cells as a novel platform for tumor-specific delivery of therapeutic antibodies. PLoS One 2009, 4:e8314.
38. Tyler M.A., Ulasov I.V., Sonabend A.M., Nandi S., Han Y., Marler S., et al. Neural stem cells target intracranial glioma to deliver an oncolytic adenovirus in vivo. Gene Ther 2009, 16:262-278.
39. Zhang S.C., Wernig M., Duncan I.D., Brustle O., Thomson J.A. In vitro differentiation of transplantable neural precursors from human embryonic stem cells. Nat Biotechnol 2001, 19:1129-1133.
40. Bergelson J.M., Cunningham J.A., Droguett G., Kurt-Jones E.A., Krithivas A., Hong J.S., et al. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science 1997, 275:1320-1323.
41. Xiong Z., Cheng Z., Zhang X., Patel M., Wu J.C., Gambhir S.S., et al. Imaging chemically modified adenovirus for targeting tumors expressing integrin alphavbeta3 in living mice with mutant herpes simplex virus type 1 thymidine kinase PET reporter gene. J Nucl Med 2006, 47:130-139.
42. Park J.W., Mok H., Park T.G. Epidermal growth factor (EGF) receptor targeted delivery of PEGylated adenovirus. Biochem Biophys Res Commun 2008, 366:769-774.
43. Fouletier-Dilling C.M., Bosch P., Davis A.R., Shafer J.A., Stice S.L., Gugala Z., et al. Novel compound enables high-level adenovirus transduction in the absence of an adenovirus-specific receptor. Hum Gene Ther 2005, 16:1287-1297.
44. Bosch P., Fouletier-Dilling C., Olmsted-Davis E.A., Davis A.R., Stice S.L. Efficient adenoviral-mediated gene delivery into porcine mesenchymal stem cells. Mol Reprod Dev 2006, 73:1393-1403.
45. Krasnykh V., Dmitriev I., Mikheeva G., Miller C.R., Belousova N., Curiel D.T. Characterization of an adenovirus vector containing a heterologous peptide epitope in the HI loop of the fiber knob. J Virol 1998, 72:1844-1852.
46. Lamfers M., Idema S., van Milligen F., Schouten T., van der Valk P., Vandertop P., et al. Homing properties of adipose-derived stem cells to intracerebral glioma and the effects of adenovirus infection. Cancer Lett 2009, 274:78-87.
47. Ranki T., Kanerva A., Ristimaki A., Hakkarainen T., Sarkioja M., Kangasniemi L., et al. A heparan sulfate-targeted conditionally replicative adenovirus, Ad5.pk7-Delta24, for the treatment of advanced breast cancer. Gene Ther 2007, 14:58-67.
48. Rein D.T., Breidenbach M., Wu H., Han T., Haviv Y.S., Wang M., et al. Gene transfer to cervical cancer with fiber-modified adenoviruses. Int J Cancer 2004, 111:698-704.
49. Zheng S., Ulasov I.V., Han Y., Tyler M.A., Zhu Z.B., Lesniak M.S. Fiber-knob modifications enhance adenoviral tropism and gene transfer in malignant glioma. J Gene Med 2007, 9:151-160.
50. Breidenbach M., Rein D.T., Wang M., Nettelbeck D.M., Hemminki A., Ulasov I., et al. Genetic replacement of the adenovirus shaft fiber reduces liver tropism in ovarian cancer gene therapy. Hum Gene Ther 2004, 15:509-518.
51. Seshidhar Reddy P., Ganesh S., Limbach M.P., Brann T., Pinkstaff A., Kaloss M., et al. Development of adenovirus serotype 35 as a gene transfer vector. Virology 2003, 311:384-393.
52. Knaan-Shanzer S., van de Watering M.J., van der Velde I., Goncalves M.A., Valerio D., de Vries A.A. Endowing human adenovirus serotype 5 vectors with fiber domains of species B greatly enhances gene transfer into human mesenchymal stem cells. Stem Cells 2005, 23:1598-1607.
53. Hoffmann D., Meyer B., Wildner O. Improved glioblastoma treatment with Ad5/35 fiber chimeric conditionally replicating adenoviruses. J Gene Med 2007, 9:764-778.
54. Satoh T., Arii J., Suenaga T., Wang J., Kogure A., Uehori J., et al. PILRalpha is a herpes simplex virus-1 entry coreceptor that associates with glycoprotein B. Cell 2008, 132:935-944.
55. Iankov I.D., Blechacz B., Liu C., Schmeckpeper J.D., Tarara J.E., Federspiel M.J., et al. Infected cell carriers: a new strategy for systemic delivery of oncolytic measles viruses in cancer virotherapy. Mol Ther 2007, 15:114-122.
56. Zhou G., Roizman B. Separation of receptor-binding and profusogenic domains of glycoprotein D of herpes simplex virus 1 into distinct interacting proteins. Proc Natl Acad Sci USA 2007, 104:4142-4146.
57. Menotti L., Cerretani A., Hengel H., Campadelli-Fiume G. Construction of a fully retargeted herpes simplex virus 1 recombinant capable of entering cells solely via human epidermal growth factor receptor 2. J Virol 2008, 82:10153-10161.
58. Fueyo J., Gomez Manzano C., Alemany R., Lee P.S., McDonnell T.J., Mitlianga P., et al. A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene 2000, 19:2-12.
59. Heise C., Hermiston T., Johnson L., Brooks G., Sampson-Johannes A., Williams A., et al. An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy. Nat Med 2000, 6:1134-1139.
60. Ko D., Hawkins L., Yu D.C. Development of transcriptionally regulated oncolytic adenoviruses. Oncogene 2005, 24:7763-7774.
61. Hardcastle J., Kurozumi K., Chiocca E.A., Kaur B. Oncolytic viruses driven by tumor-specific promoters. Curr Cancer Drug Targets 2007, 7:181-189.
62. Hamada K., Desaki J., Nakagawa K., Zhang T., Shirakawa T., Gotoh A., et al. Carrier cell-mediated delivery of a replication-competent adenovirus for cancer gene therapy. Mol Ther 2007, 15:1121-1128.
63. Aghi M., Visted T., Depinho R.A., Chiocca E.A. Oncolytic herpes virus with defective ICP6 specifically replicates in quiescent cells with homozygous genetic mutations in p16. Oncogene 2008, 27:4249-4254.
64. Mineta T., Rabkin S.D., Yazaki T., Hunter W.D., Martuza R.L. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat Med 1995, 1:938-943.
65. Kramm C.M., Chase M., Herrlinger U., Jacobs A., Pechan P.A., Rainov N.G., et al. Therapeutic efficiency and safety of a second-generation replication-conditional HSV1 vector for brain tumor gene therapy. Hum Gene Ther 1997, 8:2057-2068.
66. Kambara H., Okano H., Chiocca E.A., Saeki Y. An oncolytic HSV-1 mutant expressing ICP34.5 under control of a nestin promoter increases survival of animals even when symptomatic from a brain tumor. Cancer Res 2005, 65:2832-2839.
67. Chiocca E.A. Oncolytic viruses. Nat Rev Cancer 2002, 2:938-950.
68. Sterman D.H., Treat J., Litzky L.A., Amin K.M., Coonrod L., Molnar-Kimber K., et al. Adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: results of a phase I clinical trial in malignant mesothelioma. Hum Gene Ther 1998, 9:1083-1092.
69. Dewhirst M.W., Cao Y., Moeller B. Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response. Nat Rev Cancer 2008, 8:425-437.
70. Willmon C., Harrington K., Kottke T., Prestwich R., Melcher A., Vile R. Cell carriers for oncolytic viruses: Fed Ex for cancer therapy. Mol Ther 2009, 17:1667-1676.